JCRB1425 KYSE3410
Cell information
Important Notice(s)Announcement of unavailability of KYSE series cell lines to oversea users outside of Japan
Cell type：general cells (View Pricing Information)
| JCRB No. | JCRB1425 | Cell Name | KYSE3410 |
|---|---|---|---|
| Profile | Human squamous cell carcinoma cell line established from esophageal cancer. | Other Name | |
| Animal | human | Strain | |
| Genus | Homo | Species | sapiens |
| Sex | M | Age | 52 |
| Identity | available | Tissue for Primary Cancer | esophagus |
| Case history | Metastasis | ||
| Tissue Metastasized | Genetics | squamous cell carcinoma, stage 4 | |
| Life Span | infinite | Crisis PDL | |
| Morphology | epithelial-like | Character | T4M1N1 stage 4 |
| Classify | tumor | Established by | Shimada, Y. |
| Registered by | Shimada, Y. | Regulation for Distribution | |
| Comment | Year | 2011 | |
| Medium | Ham's F12 medium + RPMI1640 medium (1 to 1 mix) with 2% fetal calf serum. | Methods for Passages | Cells harvested after treatment with trypsin and EDTA. |
| Cell Number on Passage | split ratio = 1/5 | Race | |
| CO2 Conc. | 5% | Tissue Sampling | esophagus |
| Tissue Type |
| Detection of virus genome fragment by Real-time PCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Detected DNA Virus | tested | Detected RNA Virus | tested | ||||||
| CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
| EBV | - | HBV | - | HIV-1 | - | HTLV-2 | - | ||
| HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
| HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
| BKV | - | HIV-1 | - | ||||||
| JCV | - | HIV-2 | - | ||||||
| ADV | - | HPV18 | - | ||||||
| Notes | |||||||||
| Reference | |
|---|---|
| Pubmed id:17671398 | ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Tsunoda S,Okumura T,Ito T,Kondo K,Ortiz C,Tanaka E,Watanabe G,Itami A,Sakai Y,Shimada Y Oncology. 2006;71(3-4):251-8 |
LOT Information
| Cell No. | JCRB1425 | Cell Name | KYSE3410 |
|---|---|---|---|
| LOT No. | 09062011 | Lot Specification | distribution |
| Medium | RPMI1640(GIBCO) and Ham's F12 medium(SiGMA)(1/1) with 5% heat inactivated fetal bovine serum(SIGMA027K03911) | Temperature | 37 C |
| Cell Density at Seeding | 5.1-8.4x10^4 cells/sq.cm | Methods for Passages | Cells were harvested after treatment with 0.25%trypsin(GIBCO) and 0.02% EDTA.(Split ratio=1/5) |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 2.21x10^6 |
| Viability at cell freezing (%) | 99.7 | Antibiotics Used | free |
| Passage Number | p3* | PDL | NT |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NT |
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | D5S818:9,14 D13S317:8 D7S820:8,11 D16S539:10 VWA:14,16 TH01:9 AM:X TPOX:8 CSF1PO:12,13 |
| Adhesion | Yes | Exoteric Gene | NT |
| Medium for Freezing | Cell Banker BLC-1(Nihon Zenyaku Industries) | CO2 Conc. | 5 % |
| Viability immediately after thawing (%) | Additional information |
| Cell No. | JCRB1425 | Cell Name | KYSE3410 |
|---|---|---|---|
| LOT No. | 04222020 | Lot Specification | distribution |
| Medium | 1:1 mixture of Ham's F-12 medium and RPMI 1640 medium with 5% fetal bovine serum (FBS; Biowest Cat. # S1820-500) | Temperature | 37 C |
| Cell Density at Seeding | 0.9 - 1.1 x 10^5 cells/mL | Methods for Passages | Cells were harvested after treatment with 0.25% trypsin and 0.02% EDTA. |
| Doubling Time | approx. 34 hrs. | Cell Number in Vial (cells/1ml) | 6.9 x 10^6 |
| Viability at cell freezing (%) | 96.4 | Antibiotics Used | free |
| Passage Number | Unknown (6 at bank) | PDL | |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | |
| Chromosome Mode | Chromosome Information | ||
| Surface Antigen | DNA Profile (STR) | ||
| Adhesion | Yes | Exoteric Gene | |
| Medium for Freezing | 10% DMSO, 20% FBS - Ham's F-12/RPMI 1640 | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | 89.5 | Additional information |